319 related articles for article (PubMed ID: 34279719)
1. Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study.
Yue M; Zhang J; Wang X; Yan K; Cai L; Tian K; Niu S; Han X; Yu Y; Huang J; Han D; Yao J; Liu Y
Virchows Arch; 2021 Sep; 479(3):443-449. PubMed ID: 34279719
[TBL] [Abstract][Full Text] [Related]
2. The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer.
Wu S; Yue M; Zhang J; Li X; Li Z; Zhang H; Wang X; Han X; Cai L; Shang J; Jia Z; Wang X; Li J; Liu Y
Mod Pathol; 2023 Mar; 36(3):100054. PubMed ID: 36788100
[TBL] [Abstract][Full Text] [Related]
3. Improving Ki67 assessment concordance by the use of an artificial intelligence-empowered microscope: a multi-institutional ring study.
Cai L; Yan K; Bu H; Yue M; Dong P; Wang X; Li L; Tian K; Shen H; Zhang J; Shang J; Niu S; Han D; Ren C; Huang J; Han X; Yao J; Liu Y
Histopathology; 2021 Oct; 79(4):544-555. PubMed ID: 33840132
[TBL] [Abstract][Full Text] [Related]
4. Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
Jung M; Song SG; Cho SI; Shin S; Lee T; Jung W; Lee H; Park J; Song S; Park G; Song H; Park S; Lee J; Kang M; Park J; Pereira S; Yoo D; Chung K; Ali SM; Kim SW
Breast Cancer Res; 2024 Feb; 26(1):31. PubMed ID: 38395930
[TBL] [Abstract][Full Text] [Related]
5. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
6. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
7. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.
Helin HO; Tuominen VJ; Ylinen O; Helin HJ; Isola J
Virchows Arch; 2016 Feb; 468(2):191-8. PubMed ID: 26493985
[TBL] [Abstract][Full Text] [Related]
8. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.
Bilous M; Ades C; Armes J; Bishop J; Brown R; Cooke B; Cummings M; Farshid G; Field A; Morey A; McKenzie P; Raymond W; Robbins P; Tan L
Breast; 2003 Apr; 12(2):92-8. PubMed ID: 14659337
[TBL] [Abstract][Full Text] [Related]
9. HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues.
Qaiser T; Mukherjee A; Reddy Pb C; Munugoti SD; Tallam V; Pitkäaho T; Lehtimäki T; Naughton T; Berseth M; Pedraza A; Mukundan R; Smith M; Bhalerao A; Rodner E; Simon M; Denzler J; Huang CH; Bueno G; Snead D; Ellis IO; Ilyas M; Rajpoot N
Histopathology; 2018 Jan; 72(2):227-238. PubMed ID: 28771788
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.
Nishimura R; Murata Y; Mori K; Yamashiro K; Kuraoka K; Ichihara S; Taguchi K; Suzuki H; Ito M; Yamashita N
Acta Cytol; 2018; 62(4):288-294. PubMed ID: 29763896
[TBL] [Abstract][Full Text] [Related]
11. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
12. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.
Atkinson R; Mollerup J; Laenkholm AV; Verardo M; Hawes D; Commins D; Engvad B; Correa A; Ehlers CC; Nielsen KV
Arch Pathol Lab Med; 2011 Aug; 135(8):1010-6. PubMed ID: 21809992
[TBL] [Abstract][Full Text] [Related]
13. Reading immunohistochemical slides on a computer monitor--a multisite performance study using 180 HER2-stained breast carcinomas.
Nassar A; Cohen C; Albitar M; Agersborg SS; Zhou W; Lynch KA; Heyman ER; Lange H; Siddiqui MT
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):212-7. PubMed ID: 21475038
[TBL] [Abstract][Full Text] [Related]
14. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
15. HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern.
Perron M; Wen HY; Hanna MG; Brogi E; Ross DS
Arch Pathol Lab Med; 2021 Aug; 145(8):979-987. PubMed ID: 33212478
[TBL] [Abstract][Full Text] [Related]
16. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers.
Tewary S; Arun I; Ahmed R; Chatterjee S; Mukhopadhyay S
J Microsc; 2021 Jan; 281(1):87-96. PubMed ID: 32803890
[TBL] [Abstract][Full Text] [Related]
17. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
Green IF; Zynger DL
Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
[TBL] [Abstract][Full Text] [Related]
18. HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.
Edelweiss M; Sebastiao APM; Oen H; Kracun M; Serrette R; Ross DS
Cancer Cytopathol; 2019 Nov; 127(11):684-690. PubMed ID: 31544361
[TBL] [Abstract][Full Text] [Related]
19. Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers.
Shui R; Liang X; Li X; Liu Y; Li H; Xu E; Zhang Z; Lian Y; Guo S; Yao M; Yang H; Xu F; Liu Y; Liu J; Guo D; Wang K; Li J; Ma Y; Wang J; Shi J; Bu H; Yang W
Clin Breast Cancer; 2020 Feb; 20(1):e65-e74. PubMed ID: 31669267
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]